Signal
Roche and Genentech halt development of muscle growth antibody for rare diseases
Roche has stopped development of its experimental SMA drug emugrobart after it failed to consistently improve muscle growth and motor function in a key study.
rss
clinical_trialsdrug_developmentrare_diseasessafety_signals
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- BioPharma Divebiopharmadive.com
- Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost mus...Fierce Biotech